Weekly Monoclonal Antibodies Allocations Announced

The HHS Office of the Assistant Secretary for Preparedness and Response announced today it would distribute 148,968 anti-SARS-CoV-2 monoclonal antibodies (mAbs) to U.S. states, territories, and agencies this week.

Beginning today (Feb. 28, 2022), the currently Authorized mAbs products will be distributed:

• Sotrovimab (Xevudy) = 46,986 ​doses
• Evusheld (tixagevimab / cilgavimab) = 49,992​ ​doses
• Eli Lilly's Bebtelovimab = 51,990​ ​doses

The actual weekly distribution list is posted on this webpage.

Since Sept. 24, 2021, the U.S. government has distributed about 3.832 million mAbs.

According to the U.S. NIH, specific mAbs are effective against SARS-CoV-2 virus variants, including Omicron and its subvariants. 

And the U.K.'s Health Security Agency and the WHO publish SARS-CoV-2 variant findings on this webpage. 

Previously, the NIH announced on Feb. 24, 2022, an updated version of the COVID-19 Treatment Guidelines Panel. 

Additional breaking news regarding mAbs is published at PrecisionVaccinations.com/antibody.